RCS - Frontier IP Group - The Vaccine Group appoints Jeremy Salt as CEO

Frontier IPAnnouncement

06/05/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210506:nRSF5415Xa&default-theme=true

RNS Number : 5415X  Frontier IP Group plc  06 May 2021

Reach - a non-regulatory announcement

AIM: FIPP

06 May 2021

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Portfolio news - The Vaccine Group appoints GALVmed Chief Scientific Officer
Jeremy Salt as Chief Executive Officer

 

Frontier IP, a specialist in commercialising intellectual property, today
announces that portfolio company The Vaccine Group ("TVG" or the "Company")
has appointed Dr Jeremy Salt as Chief Executive Officer.

 

Jeremy has extensive experience in senior roles in animal healthcare across
organisations in the commercial and not-for-profit sectors. He is joining TVG
from GALVmed, a not-for-profit organisation that develops and makes available
livestock vaccines, medicines and diagnostics for small-scale livestock
producers, where he was Chief Scientific Officer. GALVmed is funded by the UK
government's Foreign, Commonwealth & Development Office through UKAID and
the Bill & Melinda Gates Foundation.

 

Before GALVmed, he was the director of Biologicals Research & Development
for the Europe, Africa and Middle East arm of the world's biggest animal
health group Zoetis, and previously the vaccines division of Pfizer Animal
Health. Jeremy has completed a PhD in the immunology of foot and mouth virus
persistence.

 

As TVG Chief Executive, Jeremy will be responsible for the continued
development and commercialisation of the Company's novel vaccine platform
technology, which is being used to develop a wide range of different vaccines
to combat zoonotic and economically-damaging diseases. These include vaccines
to combat COVID-19, Ebola, Lassa fever, African Swine Fever, porcine
respiratory and reproductive virus (PRRSV), and bovine tuberculosis.

 

The University of Plymouth spin out and its international partners have so far
been awarded more than £9 million in grants from the UK, US and Chinese
governments. It has also signed its first commercial deal with ECO Animal
Health Group plc and The Pirbright Institute to develop vaccine candidates to
combat PRRSV, one of the most economically damaging diseases to the pig
industry.  Frontier IP holds a 17 per cent equity stake in TVG.

 

 

Jeremy Salt, Chief Executive Officer of The Vaccine Group said: "I am
delighted to be taking this leadership role with The Vaccine Group at this
important time in its development. The COVID-19 pandemic has raised the
profile of vaccines as a key component of infectious disease control. The
importance of multiple technological approaches to vaccine development has
been shown to be critical. The Vaccine Group is well-positioned to contribute
to this market with its novel vaccine platform technologies."

 

Neil Crabb, Frontier IP Chief Executive Officer, said: "Jeremy's experience in
animal healthcare, including vaccines, across several major organisations will
be invaluable to The Vaccine Group as it evolves its technology, brings it to
market and develops into a successful company. We are working to strengthen
management teams across our portfolio, and we are very pleased Jeremy has
decided to join TVG. We very much look forward to working with him to make the
Company the success it deserves to be."

 

 

 

ENQUIRIES

 

 Frontier IP Group Plc                                                  T: 020 7332 2338
 Neil Crabb, Chief Executive                                            neil@frontierip.co.uk

 Andrew Johnson, Communications & Investor Relations                    M: 07464 546 025

 Company website: www.frontierip.co.uk (http://www.frontierip.co.uk/)

Fieldwork Robotics Ltd

 Rui Andres, Chief Executive

                                                                      info@fieldworkrobotics.com (mailto:info@fieldworkrobotics.com)

 Allenby Capital Limited (Nominated Adviser)

                                                                        T: 0203 328 5656
 Nick Athanas / George Payne

 

Allenby Capital Limited (Nominated Adviser)

 

 

info@fieldworkrobotics.com (mailto:info@fieldworkrobotics.com)

 

T: 0203 328 5656

Nick Athanas / George Payne

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual
property and accelerating its development through a range of commercialisation
services. A critical part of the Group's work is involving relevant industry
partners at an early stage of development to ensure technology meets real
world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence
income by taking an active involvement in spin-out companies, including
support for fund raising and collaboration with relevant industry partners at
an early stage of development.

Frontier IP is the commercialisation partner for the University of Plymouth.

ABOUT THE UNIVERSITY OF PLYMOUTH

 

The University of Plymouth is renowned for high quality, internationally
leading education, research and innovation.

 

With a mission to Advance Knowledge and Transform Lives, Plymouth is a *top 50
research university with clusters of world class research across a wide range
of disciplines including marine science and engineering, medicine,
cybersecurity and psychology. A three-time winner of the Queen's Anniversary
Prize for Higher and Further Education, most recently in 2020 in respect of
its pioneering research on microplastics pollution in the oceans and its
impact on the environment and changing behaviour, the University continues to
grow in stature and reputation.

 

It has a strong track record for teaching and learning excellence and has one
of the highest numbers of National Teaching Fellows of any UK university. With
over 19,000 students, and a further 9,500 studying for a Plymouth degree at
partner institutions in the UK and around the world, and over 135,000 alumni
pursuing their chosen careers globally, it has a growing global presence.

http://www.plymouth.ac.uk (http://www.plymouth.ac.uk)

* Research Fortnight Research Power League Table 2014.

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain.   Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADKQBBKBKBDPK